Update on move to the Main Market
Summary by AI BETAClose X
For Immediate Release 11 December 2025
CVS GROUP plc
("CVS" or the "Company" and, together with its subsidiaries, the "Group")
Update on move to the Main Market
CVS, the UK listed veterinary group and a leading provider of veterinary services, today provides an update on the proposed admission of the Company's entire issued ordinary share capital to the equity shares (commercial company) category ("ESCC") of the Official List and to trading on the main market for listed securities (the "Main Market") of the London Stock Exchange plc ("Admission").
Further to the announcement on the 24 October 2025, the Board now expects that (i) Admission will take place at 8.00 a.m. on 29 January 2026; and (ii) the ordinary shares will be cancelled from trading on AIM at 8.00 a.m. on 29 January 2026. The last day of trading in the ordinary shares on AIM is therefore expected to be 28 January 2026. Admission will be effected through an introduction of the Company's existing ordinary shares at which time the Company's admission to AIM is expected to be cancelled. Accordingly, the Company hereby gives notice of the intended cancellation of trading of its Ordinary Shares on AIM in accordance with Rule 41 of the AIM Rules for Companies. Such cancellation is not subject to shareholder approval.
Admission remains subject to a number of conditions, including (i) the approval by the FCA of a Prospectus and the ordinary shares being admitted by the FCA to the ESCC segment of the Official List; and (ii) admission by the London Stock Exchange to trading of the ordinary shares on the Main Market.
Shareholders should note that the Company's shares will no longer be traded on AIM with effect from Admission and should take their own financial and taxation advice regarding the consequences of Admission.
Berenberg is acting as Sponsor exclusively to the Company and no one else in connection with the proposed Admission.
Contacts
CVS Group plc via Camarco
Richard Fairman, CEO
Robin Alfonso, CFO
Paul Higgs, Chief Veterinary Officer
Charlotte Page, Head of Investor Relations
Berenberg (Sponsor & Joint Broker) +44 (0)20 3207 7800
Toby Flaux / Michael Burke / Milo Bonser / Brooke Harris-Lowing
Peel Hunt LLP (Nominated Adviser & Joint Broker) +44 (0)20 7418 8900
Christopher Golden / James Steel / Andrew Clark
Camarco (Financial PR) cvsg@camarco.co.uk
Ginny Pulbrook +44 (0)7961 315 138
Letaba Rimell
Tilly Butcher
About CVS Group plc (www.cvsukltd.co.uk)
CVS Group is an AIM-listed provider of veterinary services with operations in the UK and Australia. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.
The Group now operates c.470 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").
The Group employs c.8,900 personnel, including c.2,400 veterinary surgeons and c.3,300 nurses.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund